Literature DB >> 3922376

Enhancement of peroxisomal beta-oxidation in the liver of rats and mice treated with valproic acid.

S Horie, T Suga.   

Abstract

The effects of valproic acid on peroxisomal beta-oxidation and on lipid levels of liver and serum in the rat and mouse were studied. When the animals were fed diet containing 1% valproic acid for 2 weeks, the activity of peroxisomal beta-oxidation increased 4-fold in the rat liver and 2-fold in the mouse liver. Other peroxisomal enzymes such as catalase and urate oxidase also increased by the treatment though to a lesser extent than beta-oxidation. The contents of triglyceride and cholesterol in the serum decreased significantly in the rat but not in the mouse. The time course curves of the activities of cyanide-insensitive palmitoyl-CoA oxidation and carnitine-dependent palmitoyltransferase indicated that peroxisomal beta-oxidation was enhanced more rapidly than that of mitochondrial. The distributions of these enzymes were not changed by the treatment with valproic acid, though increases in liver weight and protein content were observed. These results indicate that the action of valproic acid in enhancing hepatic beta-oxidation is similar to that of clofibrate and other hypolipidemic drugs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922376     DOI: 10.1016/0006-2952(85)90670-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia.

Authors:  Deanna L Kelly; Robert R Conley; Stephanie Feldman; Yang Yu; Robert P McMahon; Charles M Richardson
Journal:  Psychiatr Q       Date:  2006

Review 2.  Biochemical relationships between Reye's and Reye's-like metabolic and toxicological syndromes.

Authors:  J Osterloh; W Cunningham; A Dixon; D Combest
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

3.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Authors:  M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

4.  Assessment of asymmetric dimethylarginine and homocysteine in epileptic children receiving antiepileptic drugs.

Authors:  Asmaa A Mahmoud; Hesham M Aboelghar; Sabry Moawad Abdelmageed; Heba M Abdallah; Mohamed I Garib; Nahla M S Abd El Hady
Journal:  Pediatr Res       Date:  2022-06-10       Impact factor: 3.756

Review 5.  Valproate-associated hepatotoxicity and its biochemical mechanisms.

Authors:  M J Eadie; W D Hooper; R G Dickinson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

6.  Inhibition of hepatic fatty acid oxidation at carnitine palmitoyltransferase I by the peroxisome proliferator 2-hydroxy-3-propyl-4-[6-(tetrazol-5-yl) hexyloxy]acetophenone.

Authors:  P S Foxworthy; P I Eacho
Journal:  Biochem J       Date:  1988-06-01       Impact factor: 3.857

7.  Neuronal peroxisome proliferator-activated receptor gamma signaling: regulation by mood-stabilizer valproate.

Authors:  Martin J Lan; Peixiong Yuan; Guang Chen; Husseini K Manji
Journal:  J Mol Neurosci       Date:  2008-04-25       Impact factor: 3.444

8.  Effects of phthalic acid esters on the liver and thyroid.

Authors:  R H Hinton; F E Mitchell; A Mann; D Chescoe; S C Price; A Nunn; P Grasso; J W Bridges
Journal:  Environ Health Perspect       Date:  1986-12       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.